Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone pulse therapy with or without orbital radiotherapy for active moderately severe Graves' orbitopathy
NL-OMON47457Phase 4Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methylprednisolone in Graves' ophthalmopathy (TED) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Composite improvement status, Vertical lid aperture change and 5 more. Planned start Apr 2018; status: withdrawn.
02
Drugs
methylprednisolone
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on NL-OMON47457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47457.